Recordati Industria Chimica e Farmaceutica SpA Maintains Steady Performance

Recordati Industria Chimica e Farmaceutica SpA, commonly known as Recordati SpA, is a prominent player in the pharmaceutical sector. The company is engaged in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products, including prescribed and non-prescription medications, pharmaceutical chemicals, therapeutic products, and treatments for rare diseases. Recordati’s products are distributed globally, underscoring its international presence.

In its recent earnings call, Recordati highlighted its stable financial performance. The company’s stock has experienced fluctuations within a specific range over the past year. The 52-week high was recorded at €60.95 in February 2025, while the low was €43.98 in April 2025. As of the last trading day on June 22, 2025, the stock closed at €53.9.

Financial metrics indicate a moderate valuation for Recordati. The price-to-earnings (P/E) ratio stands at 26.31, suggesting that investors are willing to pay €26.31 for every euro of earnings. Additionally, the price-to-book (P/B) ratio is 5.55, reflecting the market’s valuation of the company’s assets.

Recordati’s market capitalization is €11.15 billion, positioning it as a significant entity within the healthcare sector. The company is listed on the Borsa Italiana Electronic Share Market, with its financial activities denominated in euros.

Overall, Recordati Industria Chimica e Farmaceutica SpA continues to demonstrate resilience and stability in its operations, maintaining a steady performance in the competitive pharmaceutical industry.